Sign in

    Samantha

    Vice President and Equity Research Analyst at Piper Sandler & Co.

    Samantha Graham is a Vice President and Equity Research Analyst at Piper Sandler & Co., specializing in the coverage of specialty pharmaceuticals and biopharmaceutical companies. She focuses on a range of firms such as Amgen, Vertex Pharmaceuticals, and Jazz Pharmaceuticals, providing actionable investment insights backed by a success rate exceeding 60% and consistent above-market return performance as tracked by TipRanks. Samantha began her career in equity research in 2014 and joined Piper Sandler in 2017 after holding roles at RBC Capital Markets and Leerink Partners, building a robust reputation for clinical and regulatory analysis. She is registered with FINRA and holds Series 7, 63, 86, and 87 securities licenses.

    Samantha's questions to SI-BONE (SIBN) leadership

    Samantha's questions to SI-BONE (SIBN) leadership • Q3 2024

    Question

    Samantha, on behalf of Matthew O'Brien at Piper Sandler, inquired about the potential top-line contribution from the new TPT status for Bedrock Granite in 2025. She also asked for early physician feedback on the recently launched TNT pelvic fracture device.

    Answer

    CEO Laura Francis described the TPT for Granite, effective January 1, 2025, as a major milestone that will reimburse hospitals for 100% of the technology's cost, encouraging its use in outpatient settings. Regarding the TNT device, she reported a successful launch and strong, positive feedback from key opinion leaders on its seamless fit into surgeon workflows. She also noted the company is pursuing an NTAP for TNT, which could be effective in October 2025.

    Ask Fintool Equity Research AI

    Samantha's questions to AVITA Medical (RCEL) leadership

    Samantha's questions to AVITA Medical (RCEL) leadership • Q3 2024

    Question

    Samantha from Piper Sandler, on for Matthew O'Brien, asked for details on the Q4 guidance drivers, the impact of the CE Mark delay on 2025 growth, and the rollout plan for RECELL GO Mini.

    Answer

    CEO Jim Corbett explained that Q4 growth will be heavily driven by the burns business, which gains significant leverage from RECELL GO's efficiencies. He stated the CE Mark delay is not significant to 2025 goals and detailed the RECELL GO Mini rollout for Q1 2025, targeting trauma centers to treat smaller wounds.

    Ask Fintool Equity Research AI

    Samantha's questions to CVRx (CVRX) leadership

    Samantha's questions to CVRx (CVRX) leadership • Q3 2024

    Question

    Samantha from Piper Sandler & Co. inquired about the early impact of the updated inpatient reimbursement, asking if it has already increased adoption in that setting. She also sought details on physician feedback regarding the strategy to deepen penetration within existing accounts and the presence of multiple physician champions.

    Answer

    Executive Kevin Hykes stated it was too early to see a specific impact from the inpatient payment increase, which took effect October 1, 2024. He noted the goal is to equalize payment across settings, allowing clinical needs to dictate the site of service. Regarding account penetration, he explained that while top-performing centers have multiple champions, this is a goal for others, and the company is actively working to build these support networks to foster natural therapy adoption.

    Ask Fintool Equity Research AI